Literature DB >> 34179728

Skin vaccination with dissolvable microneedle patches incorporating influenza neuraminidase and flagellin protein nanoparticles induces broad immune protection against multiple influenza viruses.

Ye Wang1, Song Li2, Chunhong Dong1, Yao Ma1, Yufeng Song1, Wandi Zhu1, Joo Kim1, Lei Deng1, Timothy L Denning1, Sang-Moo Kang1, Mark R Prausnitz2, Bao-Zhong Wang1.   

Abstract

We generated self-adjuvanted protein nanoparticles of conserved influenza antigens and immunized mice via skin vaccination with dissolvable microneedle patches (MNPs) to increase the strength and breadth of immune responses. We produced M2e nanoparticles via ethanol desolvation, and double-layered NA1/M2e (shell/core), NA1-FliC/M2e, NA2/M2e, and NA2-FliC/M2e protein nanoparticles by chemically crosslinking influenza NA and flagellin (FliC) onto the surfaces of the M2e nanoparticles. The resulting nanoparticles retained FliC TLR5 innate signaling activity and significantly increased antigen-uptake and dendritic cell maturation in vitro. We incorporated the nanoparticles into MNPs for skin vaccination in mice. The nanoparticle MNPs significantly increased M2e and NA-specific antibody levels, the numbers of germinal center B cells, and IL-4 positive splenocytes. Double-layered nanoparticle MNP skin vaccination protected mice against homologous and heterosubtypic influenza viruses. Our results demonstrated that MNP skin vaccination of NA-FliC/M2e nanoparticles could be developed into a standalone or synergistic component of a universal influenza vaccine strategy.

Entities:  

Keywords:  Dissolvable microneedle patch; Flagellin adjuvant; Influenza NA protein nanoparticle; Skin vaccination; Universal influenza vaccine

Mesh:

Substances:

Year:  2021        PMID: 34179728      PMCID: PMC8232372          DOI: 10.1021/acsabm.1c00240

Source DB:  PubMed          Journal:  ACS Appl Bio Mater        ISSN: 2576-6422


  39 in total

Review 1.  Dendritic cells and cytokines in human inflammatory and autoimmune diseases.

Authors:  Patrick Blanco; A Karolina Palucka; Virginia Pascual; Jacques Banchereau
Journal:  Cytokine Growth Factor Rev       Date:  2008-02       Impact factor: 7.638

2.  Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection.

Authors:  Maryna C Eichelberger; Arnold S Monto
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge.

Authors:  Lei Deng; Jong R Kim; Timothy Z Chang; Han Zhang; Teena Mohan; Julie A Champion; Bao-Zhong Wang
Journal:  Virology       Date:  2017-06-13       Impact factor: 3.616

4.  Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.

Authors:  Arnold S Monto; Joshua G Petrie; Rachel T Cross; Emileigh Johnson; Merry Liu; Weimin Zhong; Min Levine; Jacqueline M Katz; Suzanne E Ohmit
Journal:  J Infect Dis       Date:  2015-04-08       Impact factor: 5.226

5.  Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection.

Authors:  Deborah M Brown; Sarah Lee; Maria de la Luz Garcia-Hernandez; Susan L Swain
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

6.  Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection.

Authors:  Bao-Zhong Wang; Rui Xu; Fu-Shi Quan; Sang-Moo Kang; Li Wang; Richard W Compans
Journal:  PLoS One       Date:  2010-11-29       Impact factor: 3.240

7.  PEG-SS-PPS: reduction-sensitive disulfide block copolymer vesicles for intracellular drug delivery.

Authors:  Simona Cerritelli; Diana Velluto; Jeffrey A Hubbell
Journal:  Biomacromolecules       Date:  2007-05-12       Impact factor: 6.988

8.  A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Authors:  Chia-Ying Wu; Yi-Chun Yeh; Jia-Tsrong Chan; Yu-Chih Yang; Ji-Rong Yang; Ming-Tsan Liu; Ho-Sheng Wu; Pei-Wen Hsiao
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

9.  Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Authors:  Teddy John Wohlbold; Raffael Nachbagauer; Haoming Xu; Gene S Tan; Ariana Hirsh; Karl A Brokstad; Rebecca J Cox; Peter Palese; Florian Krammer
Journal:  mBio       Date:  2015-03-10       Impact factor: 7.867

10.  Dual-linker gold nanoparticles as adjuvanting carriers for multivalent display of recombinant influenza hemagglutinin trimers and flagellin improve the immunological responses in vivo and in vitro.

Authors:  Chao Wang; Wandi Zhu; Bao-Zhong Wang
Journal:  Int J Nanomedicine       Date:  2017-07-04
View more
  4 in total

1.  Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats.

Authors:  Chunhong Dong; Bao-Zhong Wang
Journal:  Adv Nanobiomed Res       Date:  2021-12-07

Review 2.  The Importance of Nanocarrier Design and Composition for an Efficient Nanoparticle-Mediated Transdermal Vaccination.

Authors:  Rayen Yanara Valdivia-Olivares; Maria Rodriguez-Fernandez; María Javiera Álvarez-Figueroa; Alexis M Kalergis; José Vicente González-Aramundiz
Journal:  Vaccines (Basel)       Date:  2021-12-01

3.  Mapping the Mechanical and Immunological Profiles of Polymeric Microneedles to Enable Vaccine and Immunotherapy Applications.

Authors:  Shrey A Shah; Robert S Oakes; Senta M Kapnick; Christopher M Jewell
Journal:  Front Immunol       Date:  2022-03-14       Impact factor: 8.786

Review 4.  Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.

Authors:  Ana Sara Cordeiro; Yogita Patil-Sen; Maitreyi Shivkumar; Ronak Patel; Abdulwahhab Khedr; Mohamed A Elsawy
Journal:  Pharmaceutics       Date:  2021-12-05       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.